^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
Published date:
04/20/2021
Excerpt:
She was diagnosed with lung adenocarcinoma...She was found to have HER2 amplification (copy number:2.6)...and started on docetaxel and pembrolizumab with radiographic evidence of SD, which was sustained for 4.0 months up to the study endpoint....She was diagnosed with cT4N0M1a stage IVA lung squamous carcinoma by percutaneous lung biopsy….She received chemotherapy (carboplatin and pemetrexed) and pembrolizumab for 4 cycles followed by pembrolizumab maintenance therapy, with a complete response (CR) as her best response. The patient was still in remission at the endpoint of this study.
Secondary therapy:
docetaxel; carboplatin + pemetrexed
DOI:
10.3389/fonc.2021.633522
